JP2021532085A5 - - Google Patents

Info

Publication number
JP2021532085A5
JP2021532085A5 JP2021500801A JP2021500801A JP2021532085A5 JP 2021532085 A5 JP2021532085 A5 JP 2021532085A5 JP 2021500801 A JP2021500801 A JP 2021500801A JP 2021500801 A JP2021500801 A JP 2021500801A JP 2021532085 A5 JP2021532085 A5 JP 2021532085A5
Authority
JP
Japan
Prior art keywords
domain
domain monomer
igg1
monomer
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041293 external-priority patent/WO2020014413A2/en
Publication of JP2021532085A publication Critical patent/JP2021532085A/ja
Publication of JP2021532085A5 publication Critical patent/JP2021532085A5/ja
Withdrawn legal-status Critical Current

Links

JP2021500801A 2018-07-11 2019-07-11 ＣＴＬＡ−４を標的とする改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021532085A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862696754P 2018-07-11 2018-07-11
US62/696,754 2018-07-11
US201862743976P 2018-10-10 2018-10-10
US62/743,976 2018-10-10
PCT/US2019/041293 WO2020014413A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4

Publications (2)

Publication Number Publication Date
JP2021532085A JP2021532085A (ja) 2021-11-25
JP2021532085A5 true JP2021532085A5 (https=) 2022-07-15

Family

ID=69141692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500801A Withdrawn JP2021532085A (ja) 2018-07-11 2019-07-11 ＣＴＬＡ−４を標的とする改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20220064298A1 (https=)
EP (1) EP3820521A4 (https=)
JP (1) JP2021532085A (https=)
KR (1) KR20210044783A (https=)
CN (1) CN113395978A (https=)
AU (1) AU2019301160A1 (https=)
BR (1) BR112021000427A2 (https=)
CA (1) CA3106207A1 (https=)
IL (1) IL280014A (https=)
MX (1) MX2021000306A (https=)
WO (1) WO2020014413A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
US20230265176A1 (en) * 2020-08-14 2023-08-24 Chugai Seiyaku Kabushiki Kaisha One-armed antigen-binding molecules and uses thereof
CN117157328A (zh) * 2021-01-28 2023-12-01 儿童医院 Multabody构建体、组合物和方法
TWI879694B (zh) * 2021-06-25 2025-04-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same
WO2024260570A1 (en) * 2023-06-23 2024-12-26 CureVac SE Nucleic acid encoded antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2017025323A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
EP3423572B1 (en) * 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018068182A1 (en) * 2016-10-10 2018-04-19 Crown Bioscience (Taicang) Inc. Novel anti-ctla4 antibodies
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用

Similar Documents

Publication Publication Date Title
JP2021532085A5 (https=)
JP2021530498A5 (https=)
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
JP2020514301A5 (https=)
JP2021530989A5 (https=)
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
JP2021531756A5 (https=)
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
DE50210328D1 (de) Bispezifisches anti-cd28 antikörper-molekül
JP2020018311A5 (https=)
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
JP2020508655A5 (https=)
HRP20181069T1 (hr) Antagonistička protutijela na il-17
JP2017504578A5 (https=)
RU2013102596A (ru) МЫШИ, ЭКСПРЕССИРУЮЩИЕ ЛЕГКУЮ ЦЕПЬ С ВАРМАБЕЛЬНОЙ ОБЛАСТЬЮ α-ЧЕЛОВЕКА И КОНСТАНТНОЙ ОБЛАСТЬЮ МЫШИ
RU2007139953A (ru) Антитела к ccr5 и их применение
DE602004021702D1 (de) Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen
ATE452147T1 (de) Antikörper mit korrigierten cdr
NZ597168A (en) Dual variable domain immunoglobin and uses thereof
ATE490983T1 (de) Humane antikörper gegen das humane glycoprotein vi und deren verwendung
DE602006005200D1 (de) Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
AU2012325232A8 (en) Stable multiple antigen-binding antibody
JP2021531268A5 (https=)
NZ589434A (en) Dual variable domain immunoglobulins and uses thereof